Hydrocortisone caproate
Hydrocortisone caproate is an orally active anti-inflammatory corticosteroid ester and an ester derivative of hydrocortisone. Hydrocortisone caproate inhibits granuloma formation, induces hepatic glycogen deposition, and exerts anti-inflammatory activity. Hydrocortisone caproate can be used in research related to hemorrhoids.
For research use only. We do not sell to patients.
- CAS No.: 3593-96-2
- Formula: C27H40O6
- Molecular Weight:460.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vivo
Hydrocortisone caproate (oral; hourly; 5 doses) has equivalent liver glycogen-modulating activity to hydrocortisone alcohol when administered to fasted albino mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Holtzman rats (male, 125-150 Gm, subcutaneous cotton pellet granuloma model)[1]
-
Dosage:1000 μg, 500 μg, 250 μg, 125 μg (local per pellet); 2000 μg daily, 1000 μg daily (systemic)
-
Administration:local application; subcutaneous injection; daily; 6-7 days
-
Result:Inhibited granuloma formation by 35% at 1000 μg local dose.
Inhibited granuloma formation by 15% at 500 μg local dose.
Inhibited granuloma formation by 24% at 250 μg local dose.
Inhibited granuloma formation by 5% at 125 μg local dose.
Inhibited granuloma formation by 54% at 2000 μg daily systemic dose.
Inhibited granuloma formation by 37% at 1000 μg daily systemic dose.
-
Animal Model:Albino rats (male, ~200 Gm, diet-induced liver glycogen depletion model)[1]
-
Dosage:1.5 mg hydrocortisone acetate equivalent per 100 Gm
-
Administration:subcutaneous; daily; 6 days
-
Result:Produced a liver glycogen response of 643 mg reducing substances per 100 Gm body weight above control values.
-
Animal Model:Albino rats (male, ~200 Gm, single subcutaneous injection prolonged action model)[1]
-
Dosage:8.25 mg hydrocortisone acetate equivalent per 100 Gm
-
Administration:subcutaneous; single dose
-
Result:Produced an overall 7-day liver glycogen activity (area under curve) of 737.
Resulted in 5.5 mg of steroid absorbed over 7 days.
Achieved an activity per mg absorbed of 135 (calculated as hydrocortisone acetate).
Chemical Information
-
CAS No. 3593-96-2
-
Molecular Weight 460.60
-
Formula C27H40O6
-
SMILES
C[C@@]12[C@](CC[C@]2(O)C(COC(CCCCC)=O)=O)([H])[C@@]3([H])[C@]([C@@]4(C(CC3)=CC(CC4)=O)C)([H])[C@H](C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)